Exozymes Inc. reported a net loss of $2.3 million for the third quarter of 2025, with a year-to-date loss of $6.5 million. Operating expenses increased by $0.9 million compared to the prior year, mainly due to expanded research and development and new leadership hires. The company ended the second quarter of 2025 with $5.1 million in cash and cash equivalents, supporting operations into early Q2 2026. Business developments during the period included progress by its subsidiary NCTx on an exploratory analog program and ongoing development of assets for santalene and non-intoxicating cannabinoids. Exozymes also appointed Amy Lunzer as Chief of Staff and named co-founder Tyler Korman as Chief Scientific Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102254) on November 13, 2025, and is solely responsible for the information contained therein.
